United Therapeutics CEO Rothblatt sells $5.1m in shares

On October 14, 2026, United Therapeutics Corp (NASDAQ:UTHR) Chairperson and CEO Martine A. Rothblatt sold around $5.1 million worth of the company's common stock. The shares were sold as part of a pre-planned 10b5-1 trading strategy adopted in November 2025. Shares were purchased at prices between $526.07 and $546.00, with a final value of $541.00 per share, bringing the biotechnology company's valuation to $23.2 billion.

Despite Rothblatt's sale, the stock has gained 25% in value over the past year. The CEO also purchased 9,500 shares of United Therapeutics common stock through stock options, paying $117.76 per share, totaling $1,118,720. These options were exercised under the same trading plan and were vested in equal one-third installments on March 15, 2021, 2022, and 2023.

Rothblatt indirectly holds a share of 333,410 shares of common stock and 233,410 stock options through family trusts. Recent news includes United Therapeutics reporting a revenue miss, leading to a price target reduction by BofA Securities, while Jefferies raised its price target.